trending Market Intelligence /marketintelligence/en/news-insights/trending/7JL26oc9Pwwau3H5ZuJUVg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

NattoPharma Q2 loss narrows YOY


So, the data lakehouse is now officially a ‘thing’ – what is it and why should you care?


Industry Top Trends 2021: Oil and Gas


Charter, DIRECTV and Comcast rank as the top 'RSN-friendly' MVPDs

Industry Top Trends 2021: Metals and Mining

NattoPharma Q2 loss narrows YOY

NattoPharma ASA said its second-quarter normalized net income was a loss of 13 Norwegian øre per share, compared with the S&P Capital IQ consensus estimate of a loss of 17 øre per share.

The per-share loss decreased 56.2% year over year from 30 øre.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of 2.2 million kroner, compared with a loss of 4.6 million kroner in the prior-year period.

The normalized profit margin climbed to negative 16.6% from negative 59.9% in the year-earlier period.

Total revenue increased 72.6% year over year to 13.3 million kroner from 7.7 million kroner, and total operating expenses increased 7.0% year over year to 16.7 million kroner from 15.6 million kroner.

Reported net income totaled a loss of 3.4 million kroner, or a loss of 20 øre per share, compared to a loss of 7.2 million kroner, or a loss of 47 øre per share, in the prior-year period.

As of Aug. 17, US$1 was equivalent to 8.23 Norwegian kroner.